ReviewCancer management and research2017
Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer.
Review in Cancer management and research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival.Journal of surgical oncology · 2024Pooled it
- Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated With Cytoreductive Surgery: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.Frontiers in pharmacology · 2020Pooled it
- Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Trial
- Trial
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience.Radiology and oncology · 2026Article
- Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in 92 Patients with Peritoneal Metastases from Appendiceal Goblet Cell Adenocarcinoma.Annals of surgical oncology · 2026Article
- Impact of learning curve on outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer patients at a specialized center.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Evaluating long-term outcomes after cytoreductive surgery for colorectal peritoneal metastasis: do long survivors really exist?World journal of surgical oncology · 2025Article
- The impact of laparoscopic vs open primary colon resection on long-term outcomes after subsequent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for metachronous peritoneal metastasis.Surgical endoscopy · 2025Article
- Peritoneal Oligometastasis in Gastric Cancer: Diagnostic Strategies, Patient Selection, and Emerging Therapeutic Approaches.Journal of gastric cancer · 2025Review
- A prospective pilot study of kidney-specific biomarkers to detect acute kidney injury after cytoreduction and hyperthermic intraperitoneal chemotherapy.Asian biomedicine : research, reviews and news · 2024Article
- Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin.CPT: pharmacometrics & systems pharmacology · 2024Article
- Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases.Annals of surgical oncology · 2024Article
- Article
- Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases.Cancers · 2023Article
- Impact of myometrium invasion on survival outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).Journal of surgical oncology · 2023Article
- [Current status of surgical treatment of peritoneal metastases from colorectal cancer].Chirurgie (Heidelberg, Germany) · 2022Review
- The effect of metastasis location on outcome after cytoreductive surgery and heated intraperitoneal chemotherapy.Pleura and peritoneum · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment. First, basic principles of colorectal PM and the CRS and HIPEC treatment will be discussed. According to available literature, especially extent of peritoneal disease, completeness of cytoreduction, and signet ring cell histology have great influence on the outcome after CRS and HIPEC. Other factors that seem to have a negative prognostic value are the presence of liver metastases and the absence of treatment with neo-adjuvant systemic therapy. Prognostic models combining the above-mentioned factors, such as the Colorectal Peritoneal Metastases Prognostic Surgical Score nomogram, may provide clinically relevant tools to use in everyday practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.